Surgical Repair vs. Non-Surgical Treatment for Rotator Cuff Tears: Is Surgery Worth the Cost?

By HEOR Staff Writer

January 28, 2023

The rotator cuff, a critical component of the shoulder, plays a crucial role in stabilising the joint and facilitating arm movement. When it tears, patients face a decision: to opt for surgical repair or non-surgical treatment. This rotator cuff repair analysis presents a detailed review of both methods, shedding light on their effectiveness, safety, and cost-effectiveness.

Understanding Rotator Cuff Tears

Low-to-moderate-certainty evidence suggests that surgical repair does not result in clinically relevant differences in effect compared to non-surgical treatment for degenerative rotator cuff tears. An HTA from the Norwegian institute of public health showed that choosing exclusively non-surgical treatment over surgery can provide up to NOK 81 million in annual cost savings.

Research suggests that there are no clinically relevant differences in effect between surgical and non-surgical treatment. Few serious adverse events were reported, but we are uncertain about the absolute risks. Surgery is the most expensive alternative, and choosing non-surgical treatment over surgery can provide significant cost savings.

Reference url

Recent Posts

PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediatric Patients

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its primary endpoint with a 0.83% greater reduction i...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies

By João L. Carapinha

April 23, 2026

Europe Pharmaceutical Access is at a “very critical point,” according to Emer Cooke, Executive Director of the European Medicines Agency (EMA). The number of new drug launches in Europe has fallen by more than a third since U.S. President Donald Trump’s “most-favored-nation” (MFN) drug pricing po...